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nem azért, hogy bárki is 
elolvassa,csakis a Jóisten 
számára.
Bethe: Nem gondolod, hogy a Jóisten 
ismeri a tényeket?
Szilárd: Lehet, hogy ismeri, de a
tényeknek nem ezt a változatát.
[Leo Szilard, His version o f the Facts.
S.R. Weart &  Gertrud Weiss Szilard (Eds),
MIT Press, Cambridge, MA, 1978, p. 149.]
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N IH  Tunes Up Peer Review
To relieve stress on an overburdened grant system, N IH  has begun asking members of its 
study sections to reject up to half the applications without any panel discussion
If you're waiting for your grant proposal to be reviewed by the National Institutes 
of Health (NIH) in a handful of areas, you could soon be in for a nasty shock. 
Normally, you would expect your grant to get an exhaustive peer review, and even if it 
was rejected, you would expect a long critique from the reviewers — a critique you could 
use to modify the proposal and resubmit it. Now, however, you may be unlucky enough 
to receive a quick rejection and a short written explanation. At least you won't be kept 
waiting for more than a month to get the bad news, and you can take some comfort 
from the fact that you won't be alone.
A grinding sound. The current peer-review machine spits out very few proposals before study sections meet and 
assign scores and percentile ratings to most submissions
Up to half the grant proposals routed to selected peer review committees, or study 
sections, may be quickly rejected as part of an experiment N IH  launched last week as it 
tries to relieve the pressure on its overloaded peer-review system. If the experiment, 
which NIH  calls triaging, is successful, it could eventually be extended to study sections. 
The goal is to allow peer reviewers to spend more time on top proposals and less efforts 
reviewing — and re-reviewing — grants that are unlikely ever to get funded. And this 
could be just the first step in overhauling NIH's peer-review system, for N IH  officials 
are also talking about refocusing study sections and '•relying on electronic data 
submission.
These changes are signs that NIH  has recognized that, after nearly half a century of 
reliable service, the engine of peer review has begun to show signs of wear and tear and 
needs tune-up. Harold Varmus, director of NIH, says reviewers complain about the 
'’arbitrary" decisions they must make, the welter of "low-priority applications" they 
must review, and the number of repeat submissions they're seeing. Microbiologist 
Charles Moran of Emory University, who recently ended a stint on an N IH  review
panel, calls the experience "incredibly frustrating" and says he doesn't want to repeat it.
(Continued on next page)
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Can't say no. Peer reviewers over the years have found it harder and harder to 
reject a proposal at the outset.
At its core, the problem is a fiscal one: Too many good 
ideas are chasing too few dollars. The heavy demand — only 
21% of proposals are funded, most at less than the original 
request — forces study section members to pick and choose 
among equally good proposals. What's worse, they must make 
such life-or-death decisions without time to consider fully the 
merits of each proposal.
Moran says that N IH 's system is mired in paperwork, 
much of it pointless. In 1993, for example, N IH  received 19,072 
new and competing requests for small, investigator-initiated 
proposals that N IH  calls R O l grants; it funded only 4121 of 
them. Virtually all the 14,951 applications that didn't make it 
were fully reviewed, critiqued, and sent back with extensive 
comments — even if they stood no chance of being funded. 
Moreover, the system is now swamped with second- and third- 
time visitors: The number of revised grants among the 
submissions has increased from 25% in 1980 to 34% in 1992. 
AIDS researchers Jay Levy of the University of California, San 
Francisco, for one, not only bemoans the time spent reviewing 
resubmissions but also questions the wisdom of some of the 
final decisions. He says people are "coming back again and 
again" until the review panel finally surrenders and says, "My 
god, give it to him!”
Moran and Levy — like many others — find the process 
particularly discouraging because of the difficulty of making 
distinctions among grants in the middle range — those beyond 
the top 10% but within the top quartile. Yet this is exactly 
where the ax falls when N IH  draws a "pay line" dividing the 
fundable from nonfundable in what many reviewers consider to 
be an arbitrary, and, Moran adds, "depressing" process.
But relief — or at least an expression of sympathy — is on 
the way. Even before he came to NIH , Varmus had been 
talking about the need for improvements (Science, 26 
November 1993, p. 1364), and last week he put the experiment 
in triaging into effect. The goal is to eliminate the least viable 
proposals — the bottom half of those submitted — before they 
are discussed at the meetings of the study sections. Triaging has 
already begun in four study sections that met during the last 
week of February and early March (Cellular Biology and 
Physiology-2, Human Development and Aging-1, 
Metallobiochemistry, and Experimental Virology). Within the
next 2 weeks, the first letters bearing a new acronym — "N C" 
for not competitive" — will be mailed to applicants who failed 
to make the cut. That's when Varmus and his staff will begin to 
hear how the community likes it.
A strong backbone
Triaging isn't entirely new to NIH. Already, according to 
Wendy Baldwin, who was confirmed last week as NIH 's 
director of extramural research, the institutes routinely set aside 
weak proposals that arrive in response to targeted research 
efforts, called "requests for applications". But for the 
investigator-initiated grants, which N IH  calls the "traditional" 
form of biomedical research, the blunt 50% cutoff would be 
new. Thirty years ago, reviewers dropped more than one-third 
of the applications as not viable, but in recent years the number 
of "disapproved" submissions has dropped below 10%. NIH  
staffers have tried to put more steel into reviewers' backbones, 
so far with little success. However, some reviewers who spoke 
with Science — including Lawrence Rothfield of the University 
of Conneticut and Barry Honig of Columbia — said their study 
sections do practice a form of triage, by agreeing not to waste 
time discussing the least competitive grants. This sensible 
approach, says Rothfield, requires a strong chair; by endorsing 
its use, N IH  is giving others a gentle push in the same direction.
To understand how triaging is meant to work, a quick tour 
though the Byzantine structure of NIH 's granting system is 
needed. Researchers seeking new or renewed grants submit 
their proposals to NIH, which assigns them to one of about 100 
study sections. Each proposal gets a primary and secondary 
reviewer, who prepare a written critique. A third reader may 
also examine the grant and help lead the discussion during the 
formal review session. The study section meets for 3 days near 
the NIH  campus for a grueling session in which 80 proposals 
are typically dealt with. Every accepted proposals gets a score 
that is converted to percentile, after which it is forwarded to the 
advisory councils at each institute for funding or rejection. In 
1993, only 21% of the reviewed R O l proposals were funded.
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1 rying again. Resubmissions make up a growing percentage of the total number 
of R O l grant proposals sent to NIH.
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Within a couple of weeks after the study section's meeting, 
says Anthony Demsey, an official in NEH's division of research 
grants, applicants receive word of their score. It takes another 6 
to 8 weeks for the N IH  staff to compile a "pink sheet" that 
contains a summary of the reviewers' written critiques and 
comments made during the meeting. These summary sheets, 
according to Baldwin, were once brief, but they now run to 
five pages and have acquired a "tutorial" quality. Preparing 
them is one of the most ardous and time-consuming aspects of 
the review process. Triage — if it succeeds — will do away with 
some of the tutorial essays.
To streamline the process, Demsey has been instructing 
panel members in the four experimental study sections to 
regard any proposal that they would rank below the 50th 
percentile as being "not competitive". Before coming to the 
meeting, the reviewers draw up lists of N C  proposals. It takes 
two to nominate a grant for this status, and just one objection 
would "bring it back to full review." Proposals remaining on 
the list at the first day of the meeting receive no further review. 
Other proposals are handled in the usual way.
The process is flexible, Demsey explains. We are not 
saying, 'Hey look, you have 100 applications; get 50 of them 
out of here.' We understand that you might have a good pool 
of applications. Maybe out of 100 only 35 would be rejected at 
the start. But he is pushing reviewers to trim the ranks early. 
Once the initial cut has been made, the NIH  staffers who assist 
the panels will quickly send out notices of rejection. And 
instead of receiving a long summary sheet, reviewers will get a 
short statement- that does little more than convey notes written 
by the primary and secondary reviewers.
This truncated process, Varmus says, is intended to give 
reviewers more time to spend on the top-ranked proposals and 
to make reviewing a more satisfying experience. Varmus is 
worried about a "self-perpetuating disenchantment" in which 
study group members get turned off by the tedium of the 
process, avoid service, and allow it to decline further. He would 
like to see "the highest quality people" serving on panels.
Varmus also argues that quick reviews will benefit those 
who are rejected by giving them a "very clear signal that this is 
not an application that can be moved into the fundable 
category simply by responding to a series of complaints" listed 
in a pink sheet. Institute staffers, he claims, will gladly help 
with advice on "retooling", taking a new tack, or considering 
another topic.
It's too early to tell how the experiment is working, but
Demsey reports that the first panel to meet was able to isolate 
only 20% of the low-ranking grants. He notes, however, that 
this panel had already done some of its reviewers and wasn't 
able to make the adjustment to triage quickly enough. The 
second panel did achieve its goal of 50%. Others are still in 
progress. Next, N IH  will survey reviewers and reviewees for 
their reactions, and then, says Demsey, N IH  will either drop 
the triage idea, apply it to all study sections, or mount another 
trial run.
More changes ahead
If triage works, it may be just the first step in a tune-up of 
the peer-review system. NIH  has already regrouped its 100 
study sections into 19 broad "review groups" — a move that 
should make it easier to realign study groups as areas of science 
wax and wane. (NIH made the change in part to get around a 
White House mandate last spring ordering all agencies to lower 
costs by cutting the number of advisory panels by at least 33%.) 
Although the change won’t reduce paperwork or save money, 
Baldwin says it will "give us more latitude" to shift members 
from one panel to another as needed to cope with technical 
questions. It may also make it easier to change assignments and 
possibly to alter what molecular biologist Keith Yamamoto of 
the University of California, San Francisco, refers to as 
"anachronisms" that have been "locked into the system."
Other changes will be considered at a 2-day 
"brainstorming" meeting to be held this spring, organized by 
Yamamoto with encouragement from Varmus. Yamamoto 
wants N IH  staffers and reviewers in the areas of cell and 
molecular biology to consider whether study sections reflect the 
best science being done in laboratories and whether "we are 
overcovering or undercovering any areas," says Yamamoto. 
The goal, according to Yamamoto, is to help the N IH  review 
system focus on the most exciting research.
Because the peer-review system is at the heart of NIH 's 
operations, researchers are likely to be skittish about even the 
most modest changes. So N IH  officials are already bracing for 
complaints from applicants who feel they haven't been given a 
fair shake under the new system. But Yamamoto thinks that 
triage is already an unqualified success in one small way: It 
shows researchers that someone is paying attention to their 
concerns, and that's bound to improve morale.
Eliot Marshall, 
Science, 263:1212-3 (4 March 1994)
V
In science the excellent is not just better than the ordinary; it is almost all that matters. 
It is therefore fundamental that this country should energetically sustain 
and strongly reinforce first-rate work where it now exists.
(Scientific Progress, the Universities and the Federal Government, 
The White House, Washington, DC, 15 November 1960)
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Research trends 
. a performance report
Each month this feature exploits ISI's unique publication and citation data to illuminate current trends in research and to 
reveal research performance. A quantitative approach defines each story and an accompanying commentary highlights the most
prominent results of the analysis.
Top 25 U .S . Institutions in Chemistry 
Ranked by Citation Impact, 1988-1992




1 Harvard University 937 8,465 9.03
2 Caltech 821 6,817 8.30
3 Yale University 749 5,953 7.95
4 University of Chicago 713 5,606 7.86
5 Rice University 404 3,014 7.46
6 A T & T  Beli Labs 1,091 8,088 7.41
7 Northeastern University 256 1,840 7.19
8 Univ. Calif., Santa Barbara 808 5,776 7.15
9 Univ. Calif., Los Angeles 894 6,165 6.90
10 Stanford University 1,105 7,578 6.86
11 Univ. Colorado, Boulder 737 5,008 6.80
12 MIT 1,486 10,076 6.78
13 Lawrence Berkeley Laboratory 890 6,021 6.77
14 Univ. Calif., Berkeley 1,680 11,310 6.73
15 Argonne National Laboratory 885 5,818 6.57
16 Indiana University 848 5,545 6.54
17 Northwestern University 928 6,063 6.53
18 Univ. North Carolina, Chapel H il 690 4,487 6.50
19 Sar.dia National Laboratory 540 3,509 6.50
20 Univ. Calif., San Diego 625 4,053 6.48
21 Univ. Calif., Irvine 489 3,105 6.35
22 IBM 1,603 9,922 6.19
23 University of Utah 1,069 6,593 6.17
24 University of Pittsburgh 974 5,934 6.09
25 DuPont Corporation 1,177 7,123 6.05
Source: ISI s Science Indicators Database, 1988-92
New Method, New Numbers Yield 
Latest List of Chemistry's Comers
Which institutions worldwide rank at the top for recent 
research in chemistry?
That's a question Science Watch asked two years ago, when 
it drew up a list of 50 universities from around the globe that 
scored best in terms of citations per paper for chemistry articles 
published 1984-1990. The results of this survey excited much 
interest and not a little controversy in the United States and 
abroad, since in some instances peer judgment and citation 
statistics contrasted sharply. In particular, certain historically 
strong universities found themselves bested by younger up-and- 
comers. Naturally, the Young Turks hailed these findings, 
while the Old Guard grumbled about the method used. 
Different methods produce different results, as all scientists 
know. So, with this issue, Science Watch returns to ask the same 
question but in different way.
This time, chemistry articles indexed by ISI between 1988 
and 1992 were surveyed. Included in the current analysis were 
all types of journal articles, whereas previously only discovery 
accounts, reviews, and notes were counted. But the most 
significant difference in methodology this time out was the 
identification and inclusion of chemistry papers published in 
the high-impact journals Science, Nature, and Proceedings o f the 
National Academy o f Sciences o f the USA. In the last study, 
papers published in multidisciplinary journals were not 
considered because there was no way to select chemistry articles 
from among those on other subjects that also appeared within 
these titles. Now ISI's Research Department employs an 
algorithm that scans the reference lists of papers published in 
multidisciplinary journals to find those that frequently cite a 
specific field. Such papers can then be categorized or tagged, 
according to the subject area most cited. About 60-70% of these 
papers can be categorized in this way.
Although the omission of papers published in high-impact 
multidisciplinary journals was uniform for all institutions, it 
nonetheless provoked criticism in that some of the best papers 
from the various institutions had not been taken into account 
(see, for example, Science, 260[5110]:885, 14 May 1993). Science 
Watch, thus, sought to address this criticism and to look for any 
large differences in the results.
For the new ranking, only those institutions that 
published 250 or more papers were ranked. U.S. and non-U.S. 
institutions are presented separately here, since, owing to the 
large number of U.S. publications in the ISI database and the 
tendency for U.S. researchers to cite the work of colleagues in 
the United States, the citation scores for U.S. institutions are 
typically higher than those for non-U.S. institutions.
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Top 25 Non-U .S. Institutions in Chemistry 
Ranked by Citation Impact, 1988-1992




1 Tel Aviv University 394 2,522 6.40
2 Fritz Haber Institute 457 2,532 5.54
3 Weizmann Inst. Science 515 2,555 4.96
4 Max Planck Inst. Coal Research 379 1,832 4.83
5 University o f Cambridge 1,809 8,531 4.72
6 National Research Council Canada 1,339 6,296 4.70
7 University of Strasbourg 1 810 3,807 4.70
8 Max Planck Inst. Biophys. Chemistry 257 1,204 4.68
9 Swiss Federal Inst. Technology (ETH) 1,372 6,396 4.66
10 University of Basel 453 2,112 4.66
11 University of Southampton 743 3,344 4.50
12 Centre d'Etudes Nucleaires 385 1,702 4.42
13 University of Bristol 849 3,738 4.40
14 University of Lausanne 426 1,867 4.38
15 Inst. Molecular Science, Okazaki 746 3,257 4.37
16 University of Mainz 897 3,862 4.31
17 Philips Research Labs 356 1,535 4.31
18 University of Oxford 1,574 6,722 4.27
19 KFA Julich GmbH 449 1,910 4.25
20 University of Florence 576 2,445 4.24
21 State Univ. of Groningen 672 2,832 4.21
22 University of Frankfurt 488 2,038 4.18
23 University of Zurich 410 1,711 4.17
24 Australian National University 711 2,933 4.13
25 University of Sussex 714 2,928 4.10
Source: ISI's Science Indicators Database, 1988-92
Harvard tops the table among U.S. institutions, having 
placed second in the last survey. Caltech, which previously 
capped the chemistry chart, ranks second this time. Chicago, 
U C Santa Barbara, Yale, and Stanford, which turn up in the 
new top ten, also ranked in the top ten in the previous analysis. 
MIT dropped considerably from last time to this time, while 
Rice rose sharply in rank. All in all, however, the same cast of 
characters tends to appear in both lists. Notable in the new list 
are three corporations (AT&T, IBM, and DuPont) and three 
government-sponsored laboratories (Lawrence Berkeley, 
Argonne, and Sandia). These rank side by side with the top 
ranked U.S. universities.
Among non-U.S. institutions, Tel Aviv University, the 
Max Planck's Fritz Haber Institute in Berlin, and the 
Weizmann Institute rank first, second and third. Israel's strong 
showing is apparent in the national rankings for chemistry. 
1988-92, where it ranks second only to the United States in 
terms of citation impact (see Science, 260[5115]:1738, 18 June 
1993). The United Kingdom's top ranked university in 
chemistry turned out to be Cambridge, followed by 
Southampton, Bristol, Oxford, and Sussex. With the exception 
of Bristol, all scored the top rating of "5" in Britain's most 
recent assessment exercise; Bristol received a "4." Three of 
Germany's six institutions listed in the chart are affiliated with 
the Max Planck organization. Switzerland is represented by the 
ET H  and the Universities of Basel, Lausanne, and Zurich. 
Philips Labs and the State University of Groningen show the 
colors for The Netherlands, while the C EN  and the University 
of Strasbourg 1 stand tall for France. Australia, Canada, Italy 
and Japan each fielded one.
The new study surveyed a total of 393,898 chemistry 
papers published during 1988-92, which were cited a total of 
1,007,624 times by the end of 1992, for a world citations-per- 
paper average of 2,56.
Science Watch 4(6): 1-2, June 1993
Nobody before the Pythagoreans had thought that mathematical relations held the secret of the universe. 
Twenty-five centuries later, Europe is still blessed and cursed with their heritage.
To non-European civilizations, the idea that numbers are the key to both wisdom and power, seems never to have occurred.
(A rthur Koestler)
IMPART 4. cvf. 8. szám, 1994. augusztus
Chemistry panel weighs misconduct cases
An Ohio State University chemistry department 
committee, asked to assess the gravity of two findings of 
plagiarism by chemistry professor Leo A. Paquette, has 
conducted that the case involving a National Institutes of 
Health grant application was serious, but that one involving a 
National Science Foundation proposal was not. Asked to 
consider whether Paquette should be allowed to continue 
supervising graduate students and postdoctoral associates, the 
committee has recommended that Paquette reduce the size of 
his research group.
Paquette and his lawyers contend the report by the chem­
istry department’s graduate studies committee exonerates him 
of the charge in the N SF case and have asked university offi­
cials to clear him of an earlier, investigatory, committee's 
finding of scientific misconduct. Paquette and his attorneys 
reject the recommendation that this research group be limited, 
saying it based only on the N IH  incident, for which Paquette 
has accepted responsibility and has already been sanctioned. 
Further punishment would be "triple jeopardy," Paquette 
argues.
The Ohio State administration disagrees with Paquette's 
lawyers' characterization of the chemistry committee's 
conclusions. "We don't feel it's appropriate to bargain with Dr. 
Paquette over whether he committed plagiarism," says Steven J. 
McDonald, associate legal counsel in Ohio State's Office of 
Legal Affairs. The university has not acted on the chemistry 
committee's recommendations, preferring to wait until NSF's 
Office of Inspector General finishes its ongoing review of the 
case before proceeding further.
In 1992, an Ohio State investigation concluded that 
Paquette had plagiarized material from an unfunded research 
proposal, which Paquette had reviewed for NIH, by chemistry 
professor Stephen F. Martin of the University of Texas, Austin. 
Paquette did not contest the finding of scientific misconduct, 
but said his inclusion of Martin’s words and ideas in his own 
grant application was inadvertent. The university formally 
reprimanded him and the Department of Health &  Human 
Services' Office of Research Integrity barred him from serving 
on NIH  review groups or advisory committees for 10 years 
(C&EN, July 12, 1993, page 22).
In the case still under dispute, NSF asked the university to 
look into an allegation of plagiarism in regard to a paper by 
Paquette and six coauthors [/. A mer. Chem. Soc., 114, 2644 
(1992)]. The controversy concerns the introductory 
background material in the paper — but not the experiments, 
discussions, or conclusions (C&EN, Aug. 16, 1993, page 5). 
None of Paquette's coauthors are in any way implicated.
N SF specifically pointed to a sentence in the paper that 
says two cyclobutadiene rings held close to each other in a 
cydophane structure could be stabilized by more than 50 kcal 
per mole. The references cited for the 50-kcal figure do not 
contain that number, which is found, however, in an 
unsuccessful proposal to NSF that Paquette had reviewed 
earlier. The proposal cites several related studies using the very
references that turned up later in Paquette's JACS paper, even 
down to the same misspellings.
Paquette explained to the committee convened by Ohio 
State to investigate the N SF allegation that he had not learned 
of the number from the proposal, but from conversations with 
a colleague. Also, the 50-kcal figure had been made public by 
the proposal writer in a poster presented at a 1989 American 
Chemical Society meeting that Paquette had attended.
The investigatory committee found that "Paquette 
plagiarized portions of an N SF proposal... and did not treat the 
submitted material with the standards of confidentiality 
accepted by the scientific community." The committee did not 
confine its concerns to the origin of the 50-kcal number but 
concluded that Paquette condensed and paraphrased sections of 
the proposal into his paper's two introductory paragraphs. 
"Paquette's possible prior knowledge of the number does not 
alter the committee's findings that the larger body of work was 
taken by Professor Paquette without attribution."
Paquette has argued vigorously that the introduction of his 
paper resembles the NSF proposal only because they both 
summarize the same, limited background material. He admits 
that he copied citations from the proposal, but contends such 
references are in the public domain and are not confidential. He 
and his lawyers assert that if the investigatory committee had 
had any chemists among its members, it would have recognized 
that his actions were within the norms of the chemistry 
community.
The prominent chemists — Philip E. Eaton, professor of 
chemistry at the University of Chicago; George A Olah, 
professor of chemistry of the University Southern California; 
and Nobel Laureate Donald J. Cram, professor of chemistry at 
the University of California, Los Angeles — have submitted 
letters or affidavits stating they do not believe Paquette to be 
guilty of plagiarism in the NSF case.
One of the recommendations of the investigatory 
committee was that the chemistry department's graduate studies 
committee consider Paquette's authority to supervise research 
students. The chemistry committee was scheduled to meet with 
the university provost to discuss its report last week.
The 25-page report concludes "Professor Paquette's action 
in the NSF case could be considered sloppy, but do not 
constitute plagiarism by most definitions." The committee finds 
"Paquette's alleged infraction in the NSF case to be minor, 
involving information in the public domain. It was not evident 
to the [committee] that Dr. Paquette intended to deceive the 
reader. The [committee] cannot exclude the possibility that Dr. 
Paquette had actually taken known facts from the NSF 
proposal. However, we expect that when two scholars review 
the history of a shared technical specialty, there will be 
similarities in their presentation."
The chemistry committee writes that it believes Paquette's 
actions stem from attempts to "accomplish too much," noting 
that his research group has consisted of 30 to 40 people and that 
he has published 30 to 50 papers a year. It recommends he cut
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back his total number of graduate students and postdocs to 20.
"Our feeling was there was a serious misconduct in the 
NIH  case", says chemistry professor Daniel L. Leussing, who 
chaired the committee. "We don’t wish to imply we think there 
is plagiarism in the N SF case. Our position is that we can't 
determine that. Our recommendations, which we hope would 
be corrective, are absolutely based on the NIH case."
Paquette is pleased that the chemistry committee appears
to support him in the NSF case, but is unhappy with its 
recommendations. He denies that his research group is too large 
or that he tries to do too much. He is still hoping the university 
will drop the NSF case, without his having to go to court. "I 
wish I could get someone to listen to the facts," he says. "It sure 
is a lonely feeling."
Pamela Zurer, 
C&EN (March 21, 1994) p. 18
Nonagenarians Stay Active
Generally, when a reader sees a reference to a work 
published in 1926 or 1927, years in which Tadeus Reichstein 
published some of his earliest papers, he or she assumes that the 
author has long since departed this earth.
But this is a false assumption in the case of Reichstein, 
who at age 95 is still publishing. Reichstein, who shared the 
1950 Nobel Prize in physiology or medicine for discoveries 
related to the hormones of the adrenal cortex, is still hard at 
work at the Institute of Organic Chemistry at the University of 
Basel, Switzerland, actively participating in international 
collaborations.
His 1992 paper "The phloroglucinols of Dryopteris 
stenolepsis" (C.J. Widen, P. Ayras, T. Reichstein, Annales 
Botanici Fennici, 29[l]:41-54), for example, was coauthored with 
Finnish researchers from the University of Helsinki and the 
University of Turku.
In the United States, a change in a federal law may make 
nonagenarian researchers like Reichstein more common on 
university campuses. January 1 of this year marked the end of 
the exemption for university faculty to the Age Discrimination 
in Employment Act, which in essence will prohibit mandatory 
retirement for professors.
Now that U.S. faculty members don't have to retire at age 
70 — the mandatory age at many schools before the law went 
into effect — they can continue to work indefinitely. And, 
indeed, scientists who are remaining vital and active into their 
90s can already be found on American soil. It's hardly 
surprising: scientists, after all, possess a boundless curiosity. 
Their quest for new knowledge is timeless.
New Providence, N.J.-based R.R. Bowker Co.'s directory 
American Men and Women o f Science lists more than 350 
scientists who are 90 years old or older and living in North 
America. Many are no longer actively involved in their 
profession. Many are in poor health. But a select few continue 
to defy time.
While most interviewed for this article acknowledge that 
they don't quite get around the way they used to — they rarely 
attend conferences or gives lectures, for example — they all 
agree that they continue to work because they love what they 
do.
"I'm a scientist, and I keep working because I enjoy it," 
says ornithologist and evolutionary biologist Ernst Mayr, the
Alexander Agazziz Professor of Zoology, Emeritus, at Harvard 
University's Museum of Comparative Zoology, who will turn 
90 in July. "I'm interested in science, in finding new things out, 
and in communicating with the public. Why shouldn't I 
continue to work?"
Making Room for Others
Their continued high productivity notwithstanding, many 
of these mandatory retirement age. They contend that scientists 
can continue their work in other venues, and that retiring is 
often necessary to allow younger researchers and scholars the 
opportunity to make their own marks.
Take Mayr, for example. His official university retirement 
in 1975 "has been a godsend" co him, he says. He's busier than 
ever lecturing, consulting, and writing. In fact, says Mayr — 
who received the National Medal on Science in 1969 and is a 
member of the National Academy of Science (NAS) — since 
age 64 he's published nine books, and he has two more that will 
go to the publisher this year. He still writes some five to 10 
scientific papers a year.
This past January, Mayr spent the month as a visiting 
scientist at the Archbold Biological Station in Lake Placid, Fla.
"I have a very active mind," says Mayr. "Any person 
worth his salt should know what to do when retires; if he 
doesn't, he probably wasn't any good in the job to begin with. 
People should retire so young people can have opportunities."
Mayr has written some 17 books. His latest, One Long 
Argument (Harvard University Press, 1991), focuses on the 
philosophical foundations of Charles Darwin's theories of 
evolution.
A Household Name
Few scientists' careers rival that of 93-year old Linus 
Pauling, winner of two Nobel Prizes (for chemistry in 1954 and 
for peace in 1962). His 1970 book, Vitamin C and the Common 
Cold (New York, W.H. Freeman & Co.), helped make him a 
household name. When he was 73, he founded the Linus 
Pauling Institute of Science and Medicine in Palo Alto, Calif., 
where he has continued studying vitamins and disease. He 
maintains a rigorous schedule, despite having been diagnosed 
with prostate cancer two years ago.
(Continued on next page)
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"I don't lecture much anymore, but I continue to write 
and collaborate with colleagues at the institute on their research 
on vitamins," says Pauling, speaking from his ranch at Big Sur, 
some 200 miles from the Palo Alto institute, where he spends 
most of his time. He likes to devote two or three weeks of 
"high energy" at a time to a project.
Last year, he published the second edition of his book 
Cancer and Vitamin C  (Philadelphia, Camino Books), and he's 
currently collaborating on a second edition of his 1986 book, 
How to Live Longer and Feel Better (New York, W.H. Freeman 
& Co.).
"Age 70 may be too early for people to retire, with people 
living longer and healthier," Pauling says. "The previous policy 
seemed a good one. But a professor who is retired at one 
university is occasionally offered a job by another university... 
the rule never prevented another university from hiring you."
"Professors who were handicapped by age could retire; 
others, if they were healthy and wanted to continue to work, 
could [do so]," Pauling says. He retired from Stanford 
University when he was 73 rather than further abuse the 
university's retirement policy, he says. "There was no pressure 
on the administrators that way."
Why does Pauling continue to work? He has few financial 
worries; he’s paid a salary from the institute under a lifetime 
appointment. He also receives a pension from his days on 
university faculties at the California Institute of Technology, 
Stanford, and the University of California, San Diego.
Pauling, an NAS member, contends there's little else left 
for him to do, save visiting with family. "I've always been 
interested in learning new things, and have always liked 
research," he says. "I've always taken pleasure in discovering 
something new and thinking of something that no one else 
had."
Today, he keeps up with major scientific journals; in 
February, he published a "Technical Comment" in Science 
("Triethylsilyl cations," Science, 263:983). He continues to be 
interested in the fields of atomic structure and nuclear physics.
Life After Research
John T. Edsall, 91, a professor, Emeritus, of biochemistry 
at Harvard University, still walks to work daily in Cambridge, 
Mass., weather permitting. But when the biochemist-physician 
officially retired in 1973 from teaching at Harvard, he decided 
not to continue his bench research. "I had seen other people 
who continued their research into their old age, but it 
inevitably was less significant than their youth," says Edsall.
Edsall's retirement from the classroom hardly seems to 
have slowed him down. He has turned to the history of science, 
an old interest of his. Edsall also had written extensively on the 
history of the study of blood and hemoglobin. His latest 
publication came out this past December: a review of a 
bibliography of Nobel laureate Hans Krebs for Nature 
(366:417-8).
Like Pauling, Edsall has been deeply involved in social 
issues. In 1973, the American Association for the Advancement 
of Science asked him to help develop its proposed Committee 
on Scientific Freedom and Responsibility, which he later
chaired. Edsall, an NAS member, also serves on the academy's 
committee that addresses human rights violations.
Edsall's expertise is in the chemistry and structure of blood 
and muscle proteins. During the 1940s, he and his colleagues 
helped develop new uses of blood plasma proteins and blood 
fractionation processes in medicine and surgery.
Edsall says he's "somewhat concerned" about the abolition 
of mandatory faculty retirements. "Older faculty may want to 
hang on," he worries. "There may be too many holding and 
not enough opportunities for young people."
Historical Insight
Mathematician Dirk J. Struik, who will turn 100 in 
September, has little doubt he could still teach a college class in 
calculus. However, he no longer does mathematical research. 
Though early in his career he focused on tensor analysis and 
differential geometry, in the 1960s he turned to the history and 
sociology of mathematics and science. "Creative mathematics is 
for the young," he says, "but historical insight can last till the 
end."
Struik, an emeritus professor of mathematics at the 
Massachusetts Institute of Technology, taught at MIT from 
1926 to his retirement in 1960, save the five-year period during 
the McCarthy era when he was accused of subversive activities 
and suspended from the faculty.
Struik continues to work every day, "perhaps three hours, 
answering calls from colleagues and students, writing letters or 
articles and book reviews, as well as some biographical notes" 
for a planned autobiography. He remains an associate to the 
history of science department at Harvard.
"Tons of people can do good work after age 70 or 75," says 
Struik. "I didn't necessarily want to retire when I did, but I had 
to. O f course, it goes other way, too. There are those who 
should retire at age 50."
A Life s Work
"We spend a lifetime in a career doing something [we] like, 
and you don't just give that up,” says Ernest P. Hilgard, a 
professor, emeritus, of psychology and education at Stanford 
who will turn 90 in July. Hilgard, who retired from teaching in 
1969, continued an active research program from another 
decade. Today he attends a conference every so often and 
lectures on occasion. His most recent books include a history of 
psychology in the United States, which was published in 1987 
(Psychology in America: A Historical Survey, San Diego, 
Harcourt Brace Jovanovich Inc.).
Hilgard, a member of both NAS and the American 
Philosophical Society, sees nothing wrong with mandatory 
retirement. "If you want to continue to work, the university 
will almost always let you," he says. "I liked the option of a 
formal retirement. That way the administration doesn't have to 
make the decision."
Pioneering plant physiologist Paul J. Kramer, James B. 
Duke Professor of Botany, Emeritus at Duke University, who 
will celebrate his 90th birthday in May, believes that the ending 
of mandatory retirement will "create an embarrassing situation" 
for university administrations.
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"It was easy for andministrations: once you turned 70, 
they could say it's time to retire," he says. "Now they will have 
to give a great deal of thought to this."
Kramer, an NAS member and one of the founders and 
past presidents of the American Institute of Biological Sciences, 
currently is collaborating on a fourth edition of his 1949 text­
book Water Relations o f Plants (New York, McGraw-Hill Inc.).
A n Individual Decision
Meanwhile, in Canada, Gerhard Herzberg believes that 
retirement should be left to the individual, although, he says, 
"it's perfecdy acceptable to have an age of retirement — say 65, 
or 70." Herzberg is Distinguished Research Scientist at the 
Herzberg Institute of Astrophysics in Ottawa, which is a 
member institute of the National Research Council of Canada.
He won the Nobel Prize in chemistry in 1971 for his 
pioneering work in spectral analysis and molecular structure.
Herzberg plans to retire when he turns 90, on Christmas 
Day. Although there is no longer a mandatory retirement age 
for Canadian government workers, there was a mandatory age 
of 65 at the time of Herzberg's 65th birthday. (In Ontario, 
university faculty currently must retire at age 65, though other 
provinces may differ.) The mandatory age notwithstanding, 
Herzberg has kept on working past his 65th year. He was still 
discovering new molecules when he was 75.
"There should be allowances in special circumstances for 
some people to continue working,” says Herzberg. In his own 
case, the Nobel Prize was just the ticket.
Benowitz, S.,
The Scientist, (April 18, 1994)pp. 11,21, 22.
Citation Analysis Reveals Organic Chemistry's Most Active Research
In its July-August 1993 issue, the newsletter Science W atch , published by the Institute of Scientific Information (ISI) in Philadelphia, reported on its m ost recent 
examination of publishing productivity in the field of organic chemistry. U sing information from ISI's Science Indicators database, Science Watch listed the most- 
referenced papers in organic chemistry — a subdiscipline of chemistry that employs a substantial number o f research chemists — for the years 1988 to 1991.
Following is Science Watch's report, written for the newsletter by John  Ensley, who is a science writer in residence at the department o f chemistry, Imperial 
College, London. The article is reprinted here with permission o f Science Watch and ISI.
In alternating issues, Science Watch reviews the top 10 
most-cited papers in chemistry. For more than two years the 
lists have been dominated by fullerene papers, sometimes 
exclusively so, with only one occasional paper on organic 
chemistry making the grade. This is rather odd, because most 
chemists who are engaged in chemical research are using 
organic chemistry. Rather than wait for the flood tide of 
fullerene citations to ebb, Science Watch decided to look 
beneath the waves and see what pearls of organic chemistry are 
lying unnoticed.
We have combed the ISI lists of highly cited papers for the 
years 1988 through 1991, specifically seeking those that cover 
organic topics. The three top-cited papers for each year are 
listed in the accompanying table.
In drawing up the list, I considered only primary research 
papers and not reviews, which by their very nature collect 
many citations. Having carried out the citations exercise in 
organic chemistry, we then needed to check if the topics being 
cited most really were the hot areas of organic chemistry.
I consulted one of Britain's leading organic chemists, Steve 
Ley of the University of Cambridge, and asked what he 
regarded as the active areas of organic chemistry at present. His 
reply was immediate and reassuring: asymmetric synthesis 
methods, catalytic antibodies, enediynes, taxol, and 
immunosuppressants, such as rapamycin. The subjects in the 
table cover three of these current hot topics.
Jumping JA CS
The papers featured in the list are from well-known 
organic chemists: K.B. Sharpless, C.-H. Wong, D.A. Evans, E.J. 
Corey, D.P. Curran, E. Negishi, P.B. Dervan, R. Noyori, and
S.L. Schreiber. Their publications are, for the most part, short 
communications in the Journal o f the American Chemical 
Society, which attests to the continuing dominance of this 
primary journal.
Asymmetric synthesis accounts for more than a half of the 
subjects in the table, and drug-related research most of the 
remainder. Two names appear twice: K. Barry Sharpless, 
formerly of the Massachusetts Institute of Technology and now 
of the Scripps Research Institute in La Jolla, Calif., and David 
A. Evans of Harvard University, the former in the top three for 
1988 and 1989, the latter in 1988 and 1991.
Not all the articles are short communications, witness the 
1988 paper on asymmetric synthesis by Evans and colleagues. 
This runs to 19 pages, of which 10 are devoted to experimental 
details. His 1991 paper, on the other hand, is less than two 
pages long.
The first of the Evans papers deals with a variant of the Diels- 
Alder reaction, which was discovered more than 60 years ago as 
a useful method of synthesis starting with a diene and ending 
with a cyclic compound. Evans reports that unsaturated N- 
oxazolidinones make very versatile Diels-Alder reagents. (The 
oxazolidine ring is five-membered, with a nitrogen and oxygen 
atom separated by carbon.) Thesfe chiral compounds, with 
various substituents attached to the nitrogen, have several 
advantages: They are easy to make and are often crystalline; 
they are highly reactive; and, most important of all, they are 
diastereoselective, in many cases giving yields of more than 99 
percent of the endo isomer. Clearly the significance of Evans's 
discovery was not lost on others in the field, hence the 
frequency of citations.
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M ost cited papers in organic chemistry, 1988-91
Rank 1988 Total Citations
1 E.N . Jacobsen, I. Markó, W.S. M ungall, G. Schröder, K.B. Sharpless, "Asymmetric dihydroxidation via ligand-accelerated 
catalysis," Journal o f  the American Chemical Society, 110:1968-70, 1988. 154
2 Y.-F. Wang, J .J . Lalonde, M. M omongan, D .E. Bergbreiter, C.-H. Wong, "Lipase-catalyzed irreversible transesterifications using enol 
esters as acylating reagents: Preparative enantio- and regioselective syntheses of alcohols, glycerol derivatives, sugars, and 
organometallics,"/. Amer. Chem Soc., 110:7200-5, 1988. 131
3 D.A. Evans, K .T. Chapman, J .  Bisaha, "Asymmetric Diels-Alder cycloaddition reactions with chiral a , |0- unsaturated 
N-acyloxazolidinones,"J. Amer. Chem.Soc., 110:1238-56, 1988. 113
1989
1 E.J. Corey, R . Imwinkelried, S. Pikul, Y.B. Xiang, "Practical enantioselective Diels-Alder and aldol reactions using a new chiral 
controller system ,"/ Amer. Chem. Soc., 111:5493-5, 1989. 118
2 J.S.M . Wai, I. Markó, J .S . Svendsen, M .G. Finn, E.N . Jacobsen, K.B. Sharpless, "A mechanistic insight leads to a greatly 
improved osmium-catalyzed asymmetric dihydroxidation process",/. Amer. Chem. Soc.,J. Amer. Chem. Soc., 111:1123-5, 1989. 89
3 D.P. Curran, C.-T. Chang, "Atom transfer cyclization reactions of a-iodo esters, ketones, and malonates: Examples of selective 
5-Exo, 6-Endo, 6-Exo and 7- Endo ring closures," Journal o f Organic Chemistry, 54:3140-57, 1989. 88
1990
1 E. N egishi, S .J. Holm es, J.M . Tour, J.A . Miller, F.E. Cederbaum, D .R . Swanson, T. Takahashi, "Metal promoted cyclization, 
19. Novel bicyclization of enynes and diynes promoted by zirconocene derivatives and conversion of zirconabicycles into 
bicyclic enones via carbonylation,"/ Amer. Chem. Soc., 111:3336-46, 1989.* 72
2 M. Konishi, H . Ohkuma, T. Tsuno, T. O ki, G .D . VanDuyne, J . Clardy, "Crystal and molecular structure of dyemicine-A: a novel 
l,5-Dyin-3-ene antitumor antibiotic," /  Amer. Chem. Soc., 112:3715-6, 1990. 53
3 D.A. H om e, P.B. Dervan, "Recognition of mixed-sequence duplex D N A  by alternative-strand triple-helix formation," 
J. Amer. Chem. Soc., 112:2435-7, 1990. 53
1991
1 D.A. Evans, K .A . Woerpel, M.M. Hinman, M.M. Faul, "Bis(oxazolines) as chiral ligands in metal-catalyzed asymmetric reactions: 
Catalytic asymmetric cyclopropanation of olefins", /  Amer. Chem. Soc., 113:726-8, 1991 51
2 R . N oyori, M. Kitamura, "Enantioselective addition of organometallic reagents to carbonyl compounds: Chirality transfer, 
multiplication, and amplification," Angewandte Chemie-Intemational Edition in English, 30:46-9, 1991 50
3 H . Fretz, M.W. Albers, A. Galat, R .F . Standaert, W.S. Lane, S.J. Burakoff, B.E. Bierer, S.L. Schreiber, "Rapamycin and FK506 
binding proteins (im m unophillins)",/Amer. Chem. Soc., 113:1409-11, 1991. 43
*  Article apperaed late in 1989 and was not cited until 1990.
Source: ISI's Science Citation Indicators Database, 1988-92.
His 1991 paper is also devoted to asymmetric synthesis 
using bis(oxazolines) in which two of these five-membered rings 
are directly linked, or joined through an intervening carbon. 
These compounds are used in the form of Cu(I) complexes to 
catalyse the conversion of styrene to a mixture of cis and tram  
cyclopropane molecules, again with a marked preference for 
one of the forms.
And what of the future? What topics might we see heading 
a list of the most-cited papers in organic chemistry in four
years' time?
For a glimpse into the crystal ball I turned to 41-year-old 
Tony Barrett, holder of the newly created Glaxo Chair of 
Chemistry at Imperial College, London. The three topics he 
thought might be found on such a list were catalytic 
asymmetric synthesis; non-linear optical materials; and "smart" 
polymers. Would-be chemistry stars, please note.
The Scientist, (March 7,1994) IS
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m a g y a r
FüSÜQMÁNYOS AKADÉMIA  
KÖNYVTARA
Dér Forschungs index
A kutatási index 
A német kutatás vezető intézetei 
A fullerének
A befolyásosak
Intézmény Idézetek száma Publikációk száma
(1990-1993 október) (1990-1993 június)
1 Heidelbergi Max Planck Magfizikai Kutatóintézet 2148 30
2 Freiburgi Egyetem 172 18
3 Stuttgarti Max Planck Szilárdtestfizikai Kutatóintézet 123 27
4 Berlini Műszaki Egyetem 112 13
5 Karlsruhei Magkutató Központ, KfK 73 15
6 Jülichi Kutatóközpont, KfA 39 4
7 Töbingeni Egyetem 31 5
8 Berlini Hahn Meitner Intézet 24 7
9 Freie Universitat, Berlin 22 10




1 Heidelbergi Max Planck Magfizikai Kút. Int. 30
2 Stuttgarti Max Planck Szilárdtestfizikai Kút. Int. 27
3 Freiburgi Egyetem 18
4 Karlsruhei Magkutató Központ, KfK 15
5 Berlini Műszaki Egyetem 13
6 Freie Universitat, Berlin 10
7 Berlini Hahn Meitner Intézet 7
8 Wuppertali Egyetem 6
9 Tübingeni Egyetem 5
Frankfurti Egyetem 5
Karlsruhei Egyetem 5
A heidelbergi buckyball zsonglőrök 
állnak az élen
A fullerének, a molekuláris szén "futball-labdák" (bucky- 
balls) három éve a kémia legintenzívebben kutatott objektumai. 
A heidelbergi Max Planck Intézet fizikusainak, Wolfgang 
Kratschmer és Konstantinos Fostiropoulos munkái, melyekben 
1990-ben ezeknek a molekuláknak az előállítását közzétették, 
1993 októberéig már 1250 idézetet kaptak. Innen ered 
egyedülálló helyük a rangsorban. A fullerén kutatásban 
különösen tevékenyek még a stuttgarti Max Planck 
Szilárdtestfizikai Kutatóintézet fizikusai is.
A német buckyball zsonglőrökön kívül Európában 
különösen a britek közölnek a szén "futballokról" újabb 
ismereteket (lásd a grafikont). Ha a közlemények nemzetközi 
jelentőségét (az egy közleményre eső idézetek számával mérve) 
vizsgáljuk, akkor a németek után elsősorban a hollandok és a 
britek tűnnek fel, őket a svájciak és a belgák követik. Ez azt 
mutatja, hogy a kisebb pénzügy forrásokkal rendelkező kisebb 
nemzetek is hatékonyan tudnak a legaktuálisabb kutatásokban 
résztvenni.
(Forrás: Im titut fü r  Wissenschaft- und Tecbnikforschung,
Bielefeld,
a Science Citation Index alapján.)
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A hatékonyak
Intézmény Egy publikációra eső Publikációk
idézetek száma száma
1 Heidelbergi Max Planck Magfizikai Kutatóintézet 71,6 30
2 Jülichi Kutatóközpont, KfA 9,8 4
3 Freiburgi Egyetem 9,6 18
4 Berlini Műszaki Egyetem 8,6 13
5 Tübingeni Egyetem 6,2 5
6 Mainzi Max Planck Műanyagkutató Intézet 5,0 4
7 Karlsruhei Magkutató Központ, KfK 4.9 15
8 Stuttgarti Max Planck Szilárdtestfizikai Kutatóintézet 4,6 27
9 Konstanzi Egyetem 3,8 4
10 Berlini Hahn Meitner Intézet 3,4 7
Die Besten in Európa
Európa legjobbjainak "átlagos idézettsége"
Nemzetközileg a németországi fullerén-kutatások a 
legelismertebbek, átlagosan minden közleményt 18,5-szer 
idéznek a többi kutatók. Meglepetést jelent a franciák tizedik 
helye.
"A kutatási teljesítményt nem lehet rőffel mérni"
bdw: Dr. Weidemann, a médiumok közölték, hogy az új 
szövetségi tartományokban a kutatóintézetek teljesítő- 
képességének átvizsgálása után most nyugaton a "kék jegyzék” 
egyetemen kívüli intézményei kerülnek sorra.
Weidemann: Az átvizsgálások nem tekinthetők a keleti 
értékelésre adott reakciónak. Az ottani intézményeket 
elsősorban olyan szabályok szerint vizsgáltuk, melyek itt már a 
nyolcvanas évek eleje óta érvényben vannak — és a 
Tudományos Tanács döntése alapján továbbra is érvényesek 
maradnak.
bdw: Milyen módszerekkel kísérlik meg egy intézet 
teljesítőképességének felmérését?
Weidemann: Erre mindig egy bel- és külföldi
szakértőkből álló testület jogosult, ők a tudományos 
eredményeket vizsgálják. A jelentés a Szövetség-tartomány 
Bizottság elé kerül, mely a Kék jegyzék intézeteiért felelős, 
bdw: Voltaképen miért éppen "Kék jegyzékről" van szó? 
Weidemann: A név annak a papirosnak a színétől ered, 
melyre 1977-ben alapításukat rögzítették. Ezek, ellentétben a 
Max Planck intézetekkel, önálló irányítású kutatóintézetek. 
A főiskolákon kívül ezek foglalkoznak általános jelentőségű 
kutatásokkal.
bdw: Milyen következményekkel járhat a vizsgáló 
jelentése egy ilyen intézmény számára?
Weidemann: Voltak olyan esetek, amikor a Szövetség 
vagy a tartományok a pénzügyi támogatást megszüntették 
vagy csökkentették. Legtöbbször azonban megkísérlik a 
hiányzó teljesítményt az intézet átszervezésével és új kutatási 
súlypontok megállapításával elősegíteni.
bdw: Milyen szerepet játszik itt a közlemények és a más 
kutatóktól kapott idézetek összeszámlálása?
Weidemann: Ezt természetesen figyelembe veszik, de itt 
nemcsak a mennyiségről van szó. A tudományos 
teljesítményt nem lehet rőffel mérni. így például egy 
valamilyen házi kiadványban közzétett nagyszámú 
közlemény nem egyenértekű az olyan munkákkal, melyeket 
nemzetközi szakfolyóiratokban közöltek. Egy intézet 
munkáját az is minősíti, ha külső munkatársak jelentkeznek 
egy közlemény társszerzőiként, mivel úgy vélik, hogy így 
kivánnak maguknak elismerést szerezni.
(Dr. Konrad Weidemann a Mainzi Központi Múzeum 
vezérigazgatója és a "Kék jegyzék munkabizottság" vezetőségi 
szóvivője.)
Bild dér Wissenschaft, 6(1993) 6-7
Készült az A rgumentum Könyv- és Folyóiratkiadó Kft. nyomdájában Felelős kiadó: az M TAK  főigazgatója
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